Roche’s fenebrutinib shows positive results in Phase 2 FENopta study
In the Phase 2 study, which met its primary and secondary endpoints, Roche’s investigational, potent and highly selective…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
18 May 23
In the Phase 2 study, which met its primary and secondary endpoints, Roche’s investigational, potent and highly selective…
10 May 23
The consortium comprising Elliott Investment Management, an affiliate of Elliott Associates, along with healthcare investment firm Patient Square…
13 Apr 23
As part of the clinical trial support agreement, ESSA will sponsor and conduct a Phase 1 trial of…
10 Apr 23
The two companies decided to conduct a Phase 2 clinical trial of the drug after confirming the safety…
20 Feb 23
The discontinuation of US participants is due to violation of Good Clinical Practice (GCP) at certain clinical trial…
15 Feb 23
The Phase 3 clinical trial, to be conducted by Fujifilm’s subsidiary Fujifilm Toyama Chemical, and the Foundation for…
02 Jan 23
The Phase 3 study has met its primary endpoint of non-inferiority and superiority in the annualised bleeding rate…
06 Dec 22
The Phase 3 trial has met the primary endpoint of radiographic progression-free survival (rPFS) in PSMA-positive mCRPC who…
28 Nov 22
The South Korean biotech firm claimed that the anticancer therapy candidate could complete chemotherapy with two doses in…
25 Nov 22
The two-dose vaccine, which leverages the same mRNA technology used in the Covid-19 vaccines developed by Pfizer and…